Brokerages Set Akero Therapeutics, Inc. (NASDAQ:AKRO) PT at $46.83

Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $46.83.

A number of brokerages have recently issued reports on AKRO. HC Wainwright reissued a "buy" rating and issued a $50.00 price objective on shares of Akero Therapeutics in a research note on Thursday. Citigroup initiated coverage on Akero Therapeutics in a research note on Monday, November 18th. They issued a "buy" rating and a $65.00 price target on the stock.

Insider Activity at Akero Therapeutics

In other Akero Therapeutics news, insider Catriona Yale sold 4,515 shares of the business's stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $32.53, for a total transaction of $146,872.95. Following the completion of the sale, the insider now owns 74,158 shares in the company, valued at approximately $2,412,359.74. The trade was a 5.74 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Jonathan Young sold 10,000 shares of the firm's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $32.13, for a total transaction of $321,300.00. Following the completion of the transaction, the chief operating officer now directly owns 206,286 shares in the company, valued at $6,627,969.18. This trade represents a 4.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 262,135 shares of company stock valued at $8,223,000 in the last three months. Corporate insiders own 7.94% of the company's stock.

Institutional Trading of Akero Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AKRO. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Akero Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company's stock valued at $71,000 after buying an additional 446 shares during the last quarter. Eastern Bank purchased a new position in Akero Therapeutics during the 3rd quarter worth $100,000. Summit Financial Wealth Advisors LLC purchased a new position in Akero Therapeutics during the 3rd quarter worth $205,000. Victory Capital Management Inc. bought a new stake in shares of Akero Therapeutics in the 3rd quarter worth $211,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Akero Therapeutics in the third quarter valued at about $265,000.

Akero Therapeutics Trading Up 4.7 %

Akero Therapeutics stock traded up $1.13 during mid-day trading on Monday, hitting $25.14. 1,229,179 shares of the stock were exchanged, compared to its average volume of 633,147. The stock has a market capitalization of $1.75 billion, a price-to-earnings ratio of -6.70 and a beta of -0.19. Akero Therapeutics has a 12 month low of $15.32 and a 12 month high of $37.00. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. The firm's fifty day simple moving average is $28.99 and its two-hundred day simple moving average is $28.03.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its earnings results on Friday, November 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.15). Analysts forecast that Akero Therapeutics will post -3.96 EPS for the current year.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.